R+D Custom Automation Supplies Vial Machinery to SiO2 Materials Science

Article

The agreement will accelerate production of SiO2’s plastic vials for vaccines and therapeutics for Operation Warp Speed.

R+D Custom Automation, a privately-owned United States provider of automation systems, has announced an agreement with SiO2 Materials Science to supply machinery for producing SiO2’s plastic vials for storing SARS-CoV-2 vaccines and therapeutics, R+D Custom Automation announced in a July 9, 2020 press release. SiO2 was recently awarded a $143 million contract with the federal government as part of the Operation Warp Speed initiative to produce its patented plastic vials that incorporate a glass-like barrier. The contract aims for capacity to produce 40 million vials in June, 80 million in September, and 120 million in November 2020.

"We are honored to develop and manufacture the automation machinery required to produce the vials that are essential to the COVID-19 vaccine clinical trials and production," stated Loren Esch, CEO, R+D Custom Automation, in the press release. "R+D Custom Automation has been able to respond quickly, outsourcing as needed to meet machine deadlines in an accelerated timeframe. Thanks to our dedicated employees who are working long hours and weekends, what may have taken most companies eighteen months to execute, we've accomplished in a fraction of the time."

Source: R+D Custom Automation

Recent Videos
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.